Abstract
The nonergot dopamine agonist pramipexole is an efficient and safe drug for the treatment of Parkinson’s disease. Clinicians may favor pramipexole over other dopamine agonists because of its suggested higher tolerability with respect to peripheral dopaminergic side effects. Importantly, nonergot dopamine agonists such as pramipexole may not cause restrictive valvular heart disease and may therefore represent the first choice in patients with valvular lesions under treatment with ergot dopamine agonists. However, particular caution has to be exercised in younger Parkinson’s disease patients with a shorter disease duration regarding the occurrence of sudden onset of sleep. In light of cost–effectiveness and quality-of-life issues, its final significance for the initial treatment of patients with early Parkinson’s disease remains to be determined.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
